<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01182753</url>
  </required_header>
  <id_info>
    <org_study_id>CS.P.12C</org_study_id>
    <nct_id>NCT01182753</nct_id>
  </id_info>
  <brief_title>Trial of Proton Versus Carbon Ion Radiation Therapy in Patients With Low and Inter-mediate Grade Chondrosarcoma of the Skull Base</brief_title>
  <acronym>CSP12C</acronym>
  <official_title>Randomised Trial of Proton vs. Carbon Ion Radiation Therapy in Patients With Low and Inter-mediate Grade Chondrosarcoma of the Skull Base, Clinical Phase III Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective randomised clinical phase III trial. Proton therapy is the gold
      standard in the treatment of low and intermediate grad chondrosarcomas of the skull base.
      However, high-LET beams such as carbon ions theoretically offer biologic advantages by
      enhanced biologic effectiveness in slow-growing tumors. Up until now it was impossible to
      compare two different particle therapies, i.e. proton and carbon ion therapy directly with
      each other. The aim of this study is to find out, whether the biological advantages of carbon
      ion therapy mentioned above can also be clinically confirmed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective randomised clinical phase III trial. The trial will be carried out
      at Heidelberger Ionenstrahl-Therapie (HIT) centre as monocentric trial.

      Proton therapy is the gold standard in the treatment of low and intermediate grad
      chondrosarcomas of the skull base. However, high-LET beams such as carbon ions theoretically
      offer biologic advantages by enhanced biologic effectiveness in slow-growing tumors. Up until
      now it was impossible to compare two different particle therapies, i.e. proton and carbon ion
      therapy directly with each other. The aim of this study is to find out, whether the
      biological advantages of carbon ion therapy mentioned above can also be clinically confirmed.

      Patients with skull base chondrosarcomas will be randomised to either proton or carbon ion
      radiation therapy. As a standard, patients will undergo non-invasive, rigid immobilization
      and target volume definition will be carried out based on CT and MRI data. The biologically
      isoeffective target dose to the PTV in carbon ion treatment will be 60 Gy E ± 5% and 70 Gy E
      ± 5% (standard dose) in proton therapy respectively. The 5 year local-progression free
      survival (LPFS) rate will be analysed as primary end point. Overall survival, progression
      free and metastasis free survival, patterns of recurrence, local control rate and morbidity
      are the secondary end points. Plan quality is also a matter of interest.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local-Progression Free Survival (LPFS)</measure>
    <time_frame>5 years</time_frame>
    <description>The primary objective of this study is to evaluate, if the innovative carbon ion therapy in chondrosarcomas is not relevantly inferior to the standard proton treatment with respect to the 5 year LPFS rate defined as time from the randomisation to observed local reccurrence. It is assumed that the LPFS rate for the proton therapy is 90%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>12 years</time_frame>
    <description>Assessment of overall survival, progression free and metastasis free survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>12 years</time_frame>
    <description>Acute and late toxicity will be analysed according to Common Terminology Criteria for Adverse Events: CTCAE V4.0 for acute side effects and RTOG/EORTC for late reaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patterns of recurrence and local control rate</measure>
    <time_frame>5 years</time_frame>
    <description>Local recurrences will be confirmed radiologically and histologically whenever possi-ble. At least two medical doctors (radiation oncologist and/or radiologist) will be re-quired to judge of the recurrence.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">154</enrollment>
  <condition>Chondrosarcoma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A (carbon ion therapy):
Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4 - 6 days a week, 15 fractions Total dose to the PTV1 - 60 Gy E ± 5%, further 4 - 6 fractions a 3 Gy E.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm B (proton therapy):
Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4 - 6 days a week, 25 - 28 fractions Total dose to the PTV1 - 70 Gy E ± 5%, further 6 - 10 fractions a 2 Gy E.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>carbon ion therapy</intervention_name>
    <description>Arm A (carbon ion therapy):
Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4 - 6 days a week, 15 fractions Total dose to the PTV1 - 60 Gy E ± 5%, further 4 - 6 fractions a 3 Gy E.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>proton therapy</intervention_name>
    <description>Arm B (proton therapy):
Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4 - 6 days a week, 25 - 28 fractions Total dose to the PTV1 - 70 Gy E ± 5%, further 6 - 10 fractions a 2 Gy E.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Karnofsky Performance Score ≥60%

          -  Age &gt;18 years and &lt;80 years

          -  Informed consent signed by the patient

          -  Histological confirmation of low/ intermediate grade chondrosarcoma with infiltration
             of the skull base.

        Exclusion Criteria:

          -  Inability to understand the aims of the study, no informed consent

          -  Prior RT of skull base region

          -  Other malignancies with disease-free interval &lt; 5 years (excepting pre-cancerous
             lesions)

          -  Participation in another trial

          -  Pregnancy

          -  Simultaneous CHT or Immunotherapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juergen Debus, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heidelberg University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna V. Nikoghosyan, MD</last_name>
    <phone>+496221568202</phone>
    <email>anna.nikoghosyan@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juergen Debus, MD, PhD</last_name>
    <phone>+496221568202</phone>
    <email>juergen.debus@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Im neuenheimer Feld 400</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna V. Nikoghosyan, MD</last_name>
      <phone>+49 6221 568202</phone>
      <email>anna.nikoghosyan@med.uni-heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Rebecca Klumpp</last_name>
      <phone>+49 6221 5636902</phone>
      <email>rebecca.klumpp@med.uni-heidelberg.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Schulz-Ertner D, Nikoghosyan A, Hof H, Didinger B, Combs SE, Jäkel O, Karger CP, Edler L, Debus J. Carbon ion radiotherapy of skull base chondrosarcomas. Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):171-7. Epub 2006 Oct 23.</citation>
    <PMID>17056193</PMID>
  </reference>
  <reference>
    <citation>Munzenrider JE, Liebsch NJ. Proton therapy for tumors of the skull base. Strahlenther Onkol. 1999 Jun;175 Suppl 2:57-63. Review.</citation>
    <PMID>10394399</PMID>
  </reference>
  <reference>
    <citation>Ares C, Hug EB, Lomax AJ, Bolsi A, Timmermann B, Rutz HP, Schuller JC, Pedroni E, Goitein G. Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-term report. Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1111-8. doi: 10.1016/j.ijrobp.2008.12.055. Epub 2009 Apr 20.</citation>
    <PMID>19386442</PMID>
  </reference>
  <reference>
    <citation>Hug EB, Slater JD. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. Neurosurg Clin N Am. 2000 Oct;11(4):627-38. Review.</citation>
    <PMID>11082173</PMID>
  </reference>
  <reference>
    <citation>Hug EB, Loredo LN, Slater JD, DeVries A, Grove RI, Schaefer RA, Rosenberg AE, Slater JM. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. J Neurosurg. 1999 Sep;91(3):432-9.</citation>
    <PMID>10470818</PMID>
  </reference>
  <reference>
    <citation>Weber DC, Rutz HP, Pedroni ES, Bolsi A, Timmermann B, Verwey J, Lomax AJ, Goitein G. Results of spot-scanning proton radiation therapy for chordoma and chondrosarcoma of the skull base: the Paul Scherrer Institut experience. Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):401-9.</citation>
    <PMID>16168833</PMID>
  </reference>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2010</study_first_submitted>
  <study_first_submitted_qc>August 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2010</study_first_posted>
  <last_update_submitted>August 16, 2010</last_update_submitted>
  <last_update_submitted_qc>August 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Dr. J. Debus</name_title>
    <organization>University of Heidelberg</organization>
  </responsible_party>
  <keyword>Chondrosarcoma</keyword>
  <keyword>Radiation</keyword>
  <keyword>carbon ion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chondrosarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

